- Bio-Path (NASDAQ:BPTH) jumps 25% in premarket on moderate volume, after the USPTO issued a Notice of Allowance related to its lead candidate, prexigebersen, in combination with front line cytidine analogues or Bcr-Abl tyrosine kinase inhibitors, for the treatment of various cancers.
- Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2.
- Bio-Path is currently in an ongoing Phase 2 trial of prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia.
- https://seekingalpha.com/news/3624761-u-s-patent-covering-prexigebersen-lifts-bio-path
Thursday, October 22, 2020
U.S. patent covering prexigebersen lifts Bio-Path
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.